SEEKYO Therapeutics

Executive Summary

SEEKYO Therapeutics is a preclinical-stage French biotechnology company developing Tumor Activated Therapy™, a novel class of targeted cancer therapies designed to exploit the unique biochemical properties of the tumor microenvironment (TME). By inducing selective tumor self-destruction while sparing healthy tissues, the platform aims to improve the safety and efficacy of solid tumor treatments. The company's approach addresses a critical unmet need in oncology, where current therapies often lack tumor selectivity, leading to dose-limiting toxicities. Founded in 2018 and based in Paris, SEEKYO is advancing its proprietary technology through preclinical studies, with the goal of transforming solid cancer care by making potent therapies safer and more accessible. The company has not yet disclosed its lead candidate or specific development timeline, but its TME-targeted strategy positions it as an innovative player in the drug delivery and immuno-oncology space. Key milestones include validation of the platform in animal models and progression toward regulatory clearance for first-in-human trials. With a focus on solid tumors, which represent the majority of cancer cases, SEEKYO's potential to enhance therapeutic index could attract partnership interest from larger pharmaceutical companies seeking differentiated oncology assets.

Upcoming Catalysts (preview)

• H2 2026Preclinical Proof-of-Concept Data in Lead Indication70% success
• 2027Regulatory Filing for First-in-Human Trial (IND/CTA)50% success
• TBDStrategic Partnership or Licensing Agreement40% success